Cited by 1,070Cancer Genomics and DiagnosticsLung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

The DOI matches its Crossref record; 172 of the 172 references it cites were found in a registry or an index.

Combinatorial drug therapy for cancer in the post-genomic era

Al-Lazikani, Bissan, Banerji, Udai, Workman, Paul·2012·Nature Biotechnology

Open this paper in CoChat — free account

Abstract

Over the past decade, whole genome sequencing and other 'omics' technologies have defined pathogenic driver mutations to which tumor cells are addicted. Such addictions, synthetic lethalities and other tumor vulnerabilities have yielded novel targets for a new generation of cancer drugs to treat discrete, genetically defined patient subgroups. This personalized cancer medicine strategy could eventually replace the conventional one-size-fits-all cytotoxic chemotherapy approach. However, the extraordinary intratumor genetic heterogeneity in cancers revealed by deep sequencing explains why de novo and acquired resistance arise with molecularly targeted drugs and cytotoxic chemotherapy, limiting their utility. One solution to the enduring challenge of polygenic cancer drug resistance is rational combinatorial targeted therapy.

Integrity signals

Registry

Crossref · 10.1038/nbt.2284

Cites

172 of 172 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J., Lydon, N., Kantarjian, H. M., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,237
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B. J., Eisen, T. G., Stadler, W. M., Szczylik, C. A., Oudard, S. M., Siebels, M., Négrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored
Szklarczyk, D., Franceschini, A., Kuhn, M., Simonovic, M., Roth, A. C., Mínguez, P., Doerks, T., Stark, M., Muller, J., Bork, P., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq973 · Cited by 3,469
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J. K., Lindquist, D. L., Chan, S. Y. T., Romieu, C. G., Pieńkowski, T., Jagiełło-Gruszfeld, A., Crown, J. P., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,458
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. W. T. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,317
A census of human cancer genes
Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., & Stratton, M. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1299 · Cited by 3,184
Clonal evolution in cancer
Greaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643
Tumour evolution inferred by single-cell sequencing
Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., Cook, K., Stepansky, A., Levy, D., Esposito, D., et al. (2011) · Nature · doi:10.1038/nature09807 · Cited by 2,598
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
Huang, M., Ye, Y., Chen, S. R., Chai, J., Lu, J., Zhoa, L., Gu, L.-J., & Wang, Z.-Y. (1988) · Blood · doi:10.1182/blood.v72.2.567.567 · Cited by 2,445
The Database of Interacting Proteins: 2004 update
Salwinski, L. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh086 · Cited by 2,271
Chemotherapy and the war on cancer
Chabner, B. A., & Roberts, T. G. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1529 · Cited by 2,231
Global cancer transitions according to the Human Development Index (2008–2030): a population-based study
Bray, F., Jemal, A., Grey, N., Ferlay, J., & Forman, D. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70211-5 · Cited by 2,225
The Genetic Landscape of a Cell
Costanzo, M., Baryshnikova, A., Bellay, J., Kim, Y., Spear, E. D., Sevier, C. S., Ding, H., Koh, J. L. Y., Toufighi, K., Mostafavi, S., et al. (2010) · Science · doi:10.1126/science.1180823 · Cited by 2,162
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor
Joensuu, H., Roberts‎, P., Sarlomo‐Rikala, M., Andersson, L. C., Tervahartiala, P. O., Tuveson, D. A., Silberman, S., Capdeville, R., Dimitrijević, S., Druker, B. J., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441404 · Cited by 2,030
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
Baum, M., Budzar, A. U., Cuzick, J. M., Forbes, J., Houghton, J., Klijn, J. G. M., & Sahmoud, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09088-8 · Cited by 1,958
Believe it or not: how much can we rely on published data on potential drug targets?
Prinz, F., Schlange, T., & Asadullah, K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439-c1 · Cited by 1,888
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G. E., Shokat, K. M., & Rosen, N. X. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,841
Causal Protein-Signaling Networks Derived from Multiparameter Single-Cell Data
Sachs, K., Perez, O. D., Pe’er, D., Lauffenburger, D. A., & Nolan, G. P. (2005) · Science · doi:10.1126/science.1105809 · Cited by 1,785
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,764
Reactome: a database of reactions, pathways and biological processes
Croft, D., O'Kelly, G., Wu, G., Haw, R., Gillespie, M., Matthews, L., Caudy, M., Garapati, P., Gopinath, G., Jassal, B., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1018 · Cited by 1,751
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., PAQUETTE, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,614
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
Wells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, É., Elisei, R., Jarząb, B., Vasselli, J. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5040 · Cited by 1,556
Cancer Research Communications
Calura, E., Fruscio, R., Paracchini, L., Bignotti, E., Martini, P., Sales, G., Beltrame, L., Clivio, L., Ceppi, L., Di Marino, M., et al. (2021) · doi:10.1158/1078-0432 · Cited by 1,537
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Heidorn, S. J., Milagre, C. S., Whittaker, S. R., Nourry, A., Niculescu‐Duvaz, I., Dhomen, N. S., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C. A., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,497
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454
Guidelines for the welfare and use of animals in cancer research
Workman, P., Aboagye, E. O., Balkwill, F. R., Balmain, A., Bruder, G., Chaplin, D. J., Double, J. A., Everitt, J. I., Farningham, D. A. H., Glennie, M. J., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605642 · Cited by 1,450
Self-citation
DQIS — Distributed Quorum-Based Independent Immune Surveillance: A Theoretical Framework for Byzantine Fault Tolerance for Multi-Channel Immune Surveillance
DQIS Research Group (2026) · PubMed · doi:10.5281/zenodo.21937949 · Cited by 1,333
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
Personal omics profiling reveals dynamic molecular and medical phenotypes
Chen, R., Mias, G. I., Li-Pook-Than, J., Jiang, L., Lam, H. Y. K., Chen, R., Miriami, E., Karczewski, K. J., Hariharan, M., Dewey, F. E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.009 · Cited by 1,291
USE OF CHEMOTHERAPY PLUS A MONOCLONAL ANTIBODY AGAINST HER2 FOR METASTATIC BREAST CANCER THAT OVEREXPRESSES HER2
Lamon, D. E. J. S., Eyland, B. R. L., Hak, S. T. S., Uchs, H. A. F., Aton, V. I. P., Ajamonde, A. L. B., LeMing, T., Iermann, W. O. E., Olter, J. A. W., Egram, M. A. P., et al. (2009) · Cited by 1,199
Systems Biology and New Technologies Enable Predictive and Preventative Medicine
Hood, L., Heath, J. R., Phelps, M. E., & Lin, B. (2004) · Science · doi:10.1126/science.1104635 · Cited by 1,108
Pathway Commons, a web resource for biological pathway data
Cerami, E. G., Gross, B. E., Demir, E., Rodchenkov, I., Babur, O., Anwar, N., Schultz, N., Bader, G. D., & Sander, C. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1039 · Cited by 1,101
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
Scher, H. I., Beer, T. M., Higano, C. S., Anand, A., Taplin, M., Efstathiou, E., Rathkopf, D. E., Shelkey, J., Yu, E. Y., Alumkal, J. J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60172-9 · Cited by 1,063
Treatment for Adult HIV Infection
Hammer, S. M., Saag, M. S., Schechter, M., Montaner, J. S. G., Schooley, R. T., Jacobsen, D. M., Thompson, M., Carpenter, C. C. J., Fischl, M. A., Gazzard, B., et al. (2006) · JAMA · doi:10.1001/jama.296.7.827 · Cited by 1,034
A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., Wong, K.-K., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.05.006 · Cited by 1,017
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Sergina, N. V., Rausch, M., Wang, D., Blair, J. A., Hann, B. C., Shokat, K. M., & Moasser, M. M. (2007) · Nature · doi:10.1038/nature05474 · Cited by 993
A human phenome-interactome network of protein complexes implicated in genetic disorders
Lage, K., Karlberg, E., Størling, Z. M., Olason, P., Pedersen, A., Rigina, O., Hinsby, A., Tümer, Z., Pociot, F., Tommerup, N., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1295 · Cited by 973
Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?
Neckers, L., & Workman, P. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1000 · Cited by 968
Self-citation
EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer
Sobrero, A. F., Maurel, J., Fehrenbacher, L., Scheithauer, W., Abubakr, Y. A., Lutz, M. P., Vega-Villegas, M. E., Eng, C., Steinhauer, E. U., Prausová, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1193 · Cited by 955
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
Coombes, R. C., Kilburn, L., Snowdon, C. F., Paridaens, R., Coleman, R., Jones, S., Jassem, J., van de Velde, C., Delozier, T., Álvarez, I., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60200-1 · Cited by 901
Histone Deacetylase Inhibitors in Cancer Therapy
Lane, A. A., & Chabner, B. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1291 · Cited by 893
The BioGRID Interaction Database: 2011 update
Stark, C., Breitkreutz, B., Chatr‐aryamontri, A., Boucher, L., Oughtred, R., Livstone, M. S., Nixon, J., Auken, K. M. V., Wang, X., Shi, X., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq1116 · Cited by 862
Oncogene Addiction
Weinstein, I. B., & Joe, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3293 · Cited by 805
Genetic variegation of clonal architecture and propagating cells in leukaemia
Anderson, K., Lutz, C., van Delft, F. W., Bateman, C. M., Guo, Y., Colman, S., Kempski, H. M., Moorman, A. V., Titley, I., Swansbury, J. G., et al. (2010) · Nature · doi:10.1038/nature09650 · Cited by 803
Inappropriate Activation of the TSC/Rheb/mTOR/S6K Cassette Induces IRS1/2 Depletion, Insulin Resistance, and Cell Survival Deficiencies
Shah, O. J., Wang, Z., & Hunter, T. R. (2004) · Current Biology · doi:10.1016/j.cub.2004.08.026 · Cited by 800
Multicomponent therapeutics for networked systems
Keith, C. T., Borisy, A. A., & Stockwell, B. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1609 · Cited by 769
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer
Duncan, J. S., Whittle, M. C., Nakamura, K., Abell, A. N., Midland, A. A., Zawistowski, J. S., Johnson, N. L., Granger, D. A., Jordan, N. V., Darr, D. B., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.053 · Cited by 732
Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks
Lee, M. J., Ye, A. S., Gardino, A. K., Heijink, A. M., Sorger, P. K., MacBeath, G., & Yaffe, M. B. (2012) · Cell · doi:10.1016/j.cell.2012.03.031 · Cited by 681
The IntAct molecular interaction database in 2010
Aranda, B., Achuthan, P., Alam-Faruque, Y., Armean, I., Bridge, A., Derow, C., Feuermann, M., Ghanbarian, A. T., Kerrien, S., Khadake, J., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp878 · Cited by 620
The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells
Nahta, R., Hung, M., & Esteva, F. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3856 · Cited by 614
Next-generation genomics: an integrative approach
Hawkins, R. D., Hon, G. C., & Ren, B. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2795 · Cited by 608
Shape-Dependent Control of Cell Growth, Differentiation, and Apoptosis: Switching between Attractors in Cell Regulatory Networks
Huang, S., & Ingber, D. E. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.5044 · Cited by 602
PhosphoSite: A bioinformatics resource dedicated to physiological protein phosphorylation
Hornbeck, P. V., Chabra, I., Kornhauser, J. M., Skrzypek, E., & Zhang, B. (2004) · PROTEOMICS · doi:10.1002/pmic.200300772 · Cited by 598
Discovery of small molecule cancer drugs: Successes, challenges and opportunities
Hoelder, S., Clarke, P. A., & Workman, P. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.02.004 · Cited by 591
Self-citation
BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models
Li, C., Donizelli, M., Rodríguez, N., Dharuri, H. K., Endler, L., Chelliah, V., Li, L., He, E., Henry, A., Stefan, M. I., et al. (2010) · BMC Systems Biology · doi:10.1186/1752-0509-4-92 · Cited by 561
Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling
Chmielecki, J., Foo, J., Oxnard, G. R., Hutchinson, K. E., Ohashi, K., Somwar, R., Wang, L., Amato, K. R., Arcila, M. E., Sos, M. L., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002356 · Cited by 529
The expected effect of a combination of agents: the general solution
Berenbaum, M. C. (1985) · Journal of Theoretical Biology · doi:10.1016/s0022-5193(85)80176-4 · Cited by 522
Standard Short-Course Chemotherapy for Drug-Resistant Tuberculosis
Espinal, M., Kim, S., Suarez, P. G., Kam, K. M., Khomenko, A. G., Migliori, G. B., Baéz, J., Kochi, A., Dye, C., & Raviglione, M. C. (2000) · JAMA · doi:10.1001/jama.283.19.2537 · Cited by 508
MINT, the molecular interaction database: 2009 update
Ceol, A. G. M., Chatr‐aryamontri, A., Licata, L., Peluso, D., Briganti, L., Perfetto, L., Castagnoli, L., & Cesareni, G. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp983 · Cited by 507
Chemogenomic profiling: Identifying the functional interactions of small molecules in yeast
Giaever, G. N., Flaherty, P., Kumm, J., Proctor, M. J., Nislow, C., Jaramillo, D. F., Chu, A. M., Jordan, M. I., Arkin, A. P., & Davis, R. W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307490100 · Cited by 506
Circumventing cancer drug resistance in the era of personalized medicine
Garraway, L. A., & Jänne, P. A. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0012 · Cited by 503
Intratumor Heterogeneity: Seeing the Wood for the Trees
Yap, T. A., Gerlinger, M., Futreal, P. A., Pusztai, L., & Swanton, C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003854 · Cited by 501
NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis
Eccles, S. A., Massey, A., Raynaud, F. I., Sharp, S. Y., Box, G., Valenti, M. R., Patterson, L., Brandon, A. D. H., Gowan, S. M., Boxall, F. E., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5256 · Cited by 483
Self-citation
Predicting selective drug targets in cancer through metabolic networks
Folger, O., Jerby‐Arnon, L., Frezza, C., Gottlieb, E., Ruppin, E., & Shlomi, T. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.35 · Cited by 480
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases
Apsel, B., Blair, J. A., González, B., Nazif, T. M., Feldman, M. E., Aizenstein, B., Hoffman, R., Williams, R. L., Shokat, K. M., & Knight, Z. A. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.117 · Cited by 460
The Hsp90 molecular chaperone: an open and shut case for treatment
Pearl, L. H., Prodromou, C., & Workman, P. (2008) · Biochemical Journal · doi:10.1042/bj20071640 · Cited by 447
Self-citation
mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
Rodrik-Outmezguine, V. S., Chandarlapaty, S., Pagano, N. C., Poulikakos, P. I., Scaltriti, M., Moskatel, E., Baselga, J., Guichard, S., & Rosen, N. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0085 · Cited by 442
How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine
Gerlinger, M., & Swanton, C. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605912 · Cited by 439
Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma
Huang, P. H., Mukasa, A., Bonavia, R., Flynn, R. A., Brewer, Z. E., Cavenee, W. K., Furnari, F. B., & White, F. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705158104 · Cited by 383
Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing
Campbell, P. J., Pleasance, E., Stephens, P. J., Dicks, E., Rance, R., Goodhead, I., Follows, G., Green, A. R., Futreal, P. A., & Stratton, M. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801523105 · Cited by 365
DT-Diaphorase Expression and Tumor Cell Sensitivity to 17-Allylamino,17-demethoxygeldanamycin, an Inhibitor of Heat Shock Protein 90
Kèlland, L. R., Sharp, S. Y., Rogers, P., Myers, T. G., & Workman, P. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.22.1940 · Cited by 352
Self-citation
Translating cancer research into targeted therapeutics
Bono, J. S. D., & Ashworth, A. (2010) · Nature · doi:10.1038/nature09339 · Cited by 336
Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways
Yap, T. A., Omlin, A. G., & Bono, J. S. D. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.6418 · Cited by 335
Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER-2–Overexpressing Breast Cancer: A Phase I Dose-Escalation Study
Modi, S., Stopeck, A., Gordon, M. S., Mendelson, D. S., Solit, D. B., Bagatell, R., Ma, W., Wheler, J. J., Rosen, N. X., Norton, L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.7960 · Cited by 335
Gene Amplification and Drug Resistance in Cultured Murine Cells
SCHIMKE, R. T., Kaufman, R. J., Alt, F. W., & Kellems, R. F. (1978) · Science · doi:10.1126/science.715457 · Cited by 313
Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood
Higgins, M. J., Jelovac, D., Barnathan, E., Blair, B., Slater, S. A., Powers, P., Zorzi, J., Jeter, S. C., Oliver, G. R., Fetting, J. H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2696 · Cited by 311
Envisioning the future of early anticancer drug development
Yap, T. A., Sandhu, S. K., Workman, P., & Bono, J. S. D. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2870 · Cited by 280
Self-citation
Chemical combination effects predict connectivity in biological systems
Lehár, J., Zimmermann, G. R., Krueger, A. S., Molnar, R. A., Ledell, J. T., Heilbut, A. M., Short, G. F., Giusti, L. C., Nolan, G. P., Magid, O. A., et al. (2007) · Molecular Systems Biology · doi:10.1038/msb4100116 · Cited by 275
Adaptive clinical trials in oncology
Berry, D. A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.165 · Cited by 268
Spatio-temporal correlations can drastically change the response of a MAPK pathway
Takahashi, K., Tănase‐Nicola, S., & ten Wolde, P. R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906885107 · Cited by 256
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial
Albain, K. S., Barlow, W. E., Ravdin, P. M., Farrar, W. B., Burton, G. V., Ketchel, S. J., Cobau, C. D., Levine, E. G., Ingle, J. N., Pritchard, K. I., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61523-3 · Cited by 256
Utilizing RNA interference to enhance cancer drug discovery
Iorns, E. J., Lord, C. J., Turner, N. C., & Ashworth, A. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2355 · Cited by 251
Development of Novel Combination Therapies
Woodcock, J., Griffin, J. P., & Behrman, R. E. (2011) · New England Journal of Medicine · doi:10.1056/nejmp1101548 · Cited by 248
Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial
George, S., Wang, Q., Heinrich, M. C., Corless, C. L., Zhu, M. J., Butrynski, J. E., Morgan, J. A., Wagner, A. J., Choy, E., Tap, W. D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.9394 · Cited by 248
Heat Shock Protein 90 as a Drug Target: Some Like It Hot
Banerji, U. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0132 · Cited by 244
Self-citation
A global analysis of cross-talk in a mammalian cellular signalling network
Natarajan, M., Lin, K.-M., Hsueh, R. C., Sternweis, P. C., & Ranganathan, R. (2006) · Nature Cell Biology · doi:10.1038/ncb1418 · Cited by 235
Clinical Implications of the Cancer Genome
MacConaill, L. E., & Garraway, L. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4944 · Cited by 234
Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines
Kataoka, Y., Mukohara, T., Shimada, H., Saijo, N., Hirai, M., & Minami, H. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp304 · Cited by 234
Identification of CDK10 as an Important Determinant of Resistance to Endocrine Therapy for Breast Cancer
Iorns, E. J., Turner, N. C., Elliott, R. J. R., Syed, N., Garrone, O., Gasco, M., Tutt, A. N. J., Crook, T., Lord, C. J., & Ashworth, A. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.001 · Cited by 230
Die quantitativen Probleme der Pharmakologie
Loewe, S. (1928) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/bf02322290 · Cited by 226
Identification of Optimal Drug Combinations Targeting Cellular Networks: Integrating Phospho-Proteomics and Computational Network Analysis
Iadevaia, S., Lu, Y., Morales, F. C., Mills, G. B., & Ram, P. T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0460 · Cited by 219
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models
Singh, M., Lima, A., Molina, R., Hamilton, P., Clermont, A. C., Devasthali, V., Thompson, J. D., Cheng, J. H., Reslan, H. B., Ho, C., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1640 · Cited by 214
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF
Xing, F., Persaud, Y., Pratilas, C. A., Taylor, B. S., Janakiraman, M., She, Q., Gallardo, H. F., Liu, C., Merghoub, T., Hefter, B., et al. (2011) · Oncogene · doi:10.1038/onc.2011.250 · Cited by 212
Epigenetic biomarkers for human cancer: The time is now
Mulero‐Navarro, S., & Esteller, M. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.03.001 · Cited by 209
Prediction of Drug Combinations by Integrating Molecular and Pharmacological Data
Zhao, X., Iskar, M., Zeller, G., Kuhn, M., van Noort, V., & Bork, P. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002323 · Cited by 206
Anticancer therapy with checkpoint inhibitors: what, where and when?
Garrett, M. D., & Collins, I. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.02.014 · Cited by 204
A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2
Eder, J. P., Shapiro, G. I., Appleman, L. J., Zhu, A. X., Miles, D., Keer, H. N., Cancilla, B., Chu, F., Hitchcock‐Bryan, S., Sherman, L. J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0574 · Cited by 199
Chemical Genomics Identifies Small-Molecule MCL1 Repressors and BCL-xL as a Predictor of MCL1 Dependency
Wei, G., Margolin, A. A., Haery, L., Brown, E., Cucolo, L., Julian, B., Shehata, S., Kung, A. L., Beroukhim, R., & Golub, T. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.028 · Cited by 188
The biology of personalized cancer medicine: Facing individual complexities underlying hallmark capabilities
Palma, M. D., & Hanahan, D. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.01.011 · Cited by 188
Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential22Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; Cy, Cyanine; DLCL, diffuse large cell lymphoma; dNTPs, deoxyribonucleotides; ESTs, expressed sequence tags; mRNA, messenger RNA; NHL, non-Hodgkin’s lymphoma; ORF, open reading frame; RT-PCR, reverse transcription-polymerase chain reaction; and 17AAG, 17-allylamino,17-demethoxygeldanamycin.
Clarke, P. A., Poele, R. T., Wooster, R. F., & Workman, P. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00785-7 · Cited by 185
Self-citation
From an Ethics of Rationing to an Ethics of Waste Avoidance
Brody, H. A. (2012) · New England Journal of Medicine · doi:10.1056/nejmp1203365 · Cited by 173
Combination chemical genetics
Lehár, J., Stockwell, B. R., Giaever, G., & Nislow, C. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.120 · Cited by 172
Mechanisms of Resistance to Anticancer Agents
Brockman, R. W. (1963) · Advances in cancer research · doi:10.1016/s0065-230x(08)60983-5 · Cited by 152
Comparing Signaling Networks between Normal and Transformed Hepatocytes Using Discrete Logical Models
Sáez-Rodríguez, J., Alexopoulos, L. G., Zhang, M., Morris, M. K., Lauffenburger, D. A., & Sorger, P. K. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4453 · Cited by 150
Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo
Meng, J., Dai, B., Fang, B., Bekele, B. N., Bornmann, W. G., Sun, D., Peng, Z., Herbst, R. S., Papadimitrakopoulou, V. A., Minna, J. D., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014124 · Cited by 146
Pulsatile Administration of the Epidermal Growth Factor Receptor Inhibitor Gefitinib Is Significantly More Effective than Continuous Dosing for Sensitizing Tumors to Paclitaxel
Solit, D. B., She, Y., Lobo, J. M., Kris, M. G., Scher, H. I., Rosen, N. X., & Sirotnak, F. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1347 · Cited by 132
Open access chemical and clinical probes to support drug discovery
Edwards, A. M., Bountra, C., Kerr, R. S., & Willson, T. M. (2009) · Nature Chemical Biology · doi:10.1038/nchembio0709-436 · Cited by 130
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth
Chandarlapaty, S., Scaltriti, M., Angelini, P. D., Ye, Q., Guzmán, M., Hudis, C. A., Norton, L., Solit, D. B., Arribas, J., Baselga, J. M., et al. (2009) · Oncogene · doi:10.1038/onc.2009.337 · Cited by 125
Genetically Engineered Mouse Models: Closing the Gap between Preclinical Data and Trial Outcomes
Singh, M., Murriel, C. L., & Johnson, L. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2786 · Cited by 125
Acquired Resistance to 17-Allylamino-17-Demethoxygeldanamycin (17-AAG, Tanespimycin) in Glioblastoma Cells
Gaspar, N., Sharp, S. Y., Pacey, S., Jones, C., Walton, M. I., Vassal, G., Eccles, S. A., Pearson, A. D. J., & Workman, P. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3131 · Cited by 124
Self-citation
Training Signaling Pathway Maps to Biochemical Data with Constrained Fuzzy Logic: Quantitative Analysis of Liver Cell Responses to Inflammatory Stimuli
Morris, M. K., Sáez-Rodríguez, J., Clarke, D. C., Sorger, P. K., & Lauffenburger, D. A. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1001099 · Cited by 123
Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).
Infante, J. R., Falchook, G. S., Lawrence, D. P., Weber, J. S., Kefford, R. F., Bendell, J. C., Kurzrock, R., Shapiro, G. I., Kudchadkar, R. R., Long, G. V., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.18_suppl.cra8503 · Cited by 122
Reactome pathway analysis to enrich biological discovery in proteomics data sets
Haw, R., Hermjakob, H., D'Eustachio, P., & Stein, L. (2011) · PROTEOMICS · doi:10.1002/pmic.201100066 · Cited by 117
The Novel Combination of Chlorpromazine and Pentamidine Exerts Synergistic Antiproliferative Effects through Dual Mitotic Action
Lee, M. S., Johansen, L. M., Zhang, Y., Wilson, A., Keegan, M., Avery, W., Elliott, P. J., Borisy, A. A., & Keith, C. T. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2235 · Cited by 115
Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics
Yap, T. A., & Workman, P. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134532 · Cited by 107
Self-citation
Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
Shuttleworth, S. J., Silva, F. A., Cecil, A., Tomassi, C., Hill, T., Raynaud, F. I., Clarke, P. A., & Workman, P. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796011229 · Cited by 103
Self-citation
Life in the Fast Lane: Mammalian Disease Models in the Genomics Era
Dow, L. E., & Lowe, S. W. (2012) · Cell · doi:10.1016/j.cell.2012.02.023 · Cited by 83
Evolution of resistance to anti-cancer therapy during general dosing schedules
Foo, J., & Michor, F. (2009) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2009.11.022 · Cited by 83
canSAR: an integrated cancer public translational research and drug discovery resource
Halling‐Brown, M., Bulusu, K. C., Patel, M. N., Tym, J. E., & Al‐Lazikani, B. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr881 · Cited by 82
Self-citation
Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a Class I Selective Orally Active Histone Deacetylase Inhibitor
Moffat, D. F. C., Patel, S. R., Day, F. A., Belfield, A. J., Donald, A., Rowlands, M., Wibawa, J. I. D., Brotherton, D. H., Stimson, L., Clark, V., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101177s · Cited by 81
Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer
Mullenders, J., & Bernards, R. (2009) · Oncogene · doi:10.1038/onc.2009.295 · Cited by 76
A formal model for analyzing drug combination effects and its application in TNF-α-induced NFκB pathway
Yan, H., Zhang, B., Li, S., & Zhao, Q. (2010) · BMC Systems Biology · doi:10.1186/1752-0509-4-50 · Cited by 73
A Type-II Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of Bcr-Abl
Choi, H. G., Ren, P., Adrián, F., Sun, F., Lee, H. S., Wang, X., Ding, Q., Zhang, G., Xie, Y., Zhang, J., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901808w · Cited by 71
Cancer models, genomic instability and somatic cellular Darwinian evolution
Little, M. P. (2010) · Biology Direct · doi:10.1186/1745-6150-5-19 · Cited by 69
A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors.
Cosimo, S. D., Bendell, J. C., Cervantes, A. M. R., Roda, D., Prudkin, L., Stein, M. N., Leighton-Swayze, A., Song, Y., Ebbinghaus, S., & Baselga, J. M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3008 · Cited by 67
Comprehensive, atomic-level characterization of structurally characterized protein-protein interactions: the PICCOLO database
Bickerton, G. R., Higueruelo, A. P., & Blundell, T. L. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-313 · Cited by 66
Evolutionary dynamics of mutator phenotypes in cancer: implications for chemotherapy.
Komarova, N. L., & Wodarz, D. (2003) · PubMed · Cited by 66
Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling
Lu, Y., Müller, M. M., Smith, D. M., Dutta, B., Komurov, K., Iadevaia, S., Ruths, D. A., Tseng, J.-T., Yu, S., Yu, Q., et al. (2011) · Oncogene · doi:10.1038/onc.2011.164 · Cited by 65
A Blueprint for Advancing Genetics-Based Cancer Therapy
Sellers, W. R. (2011) · Cell · doi:10.1016/j.cell.2011.09.016 · Cited by 65
Computational modeling of mammalian signaling networks
Hughey, J., Lee, T. K., & Covert, M. W. (2009) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.52 · Cited by 65
High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)
Meng, J., Peng, H., Dai, B., Guo, W., Wang, L., Ji, L., Minna, J. D., Chresta, C. M., Smith, P. D., Fang, B., et al. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.21.9844 · Cited by 61
Evolutionary Modeling of Combination Treatment Strategies To Overcome Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
Mumenthaler, S. M., Foo, J., Leder, K., Choi, N. C., Agus, D. B., Pao, W. J., Mallick, P., & Michor, F. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200270v · Cited by 61
The Emperor of All Maladies
Mukherjee, S. (2010) · Cited by 57
Combining Targeted Therapies: Practical Issues to Consider at the Bench and Bedside
Rodon, J. A., Pérez-García, J. M., & Kurzrock, R. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0117 · Cited by 50
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
Kibel, A. S. (2011) · Yearbook of Urology · doi:10.1016/j.yuro.2011.05.029 · Cited by 48
CytoSolve: A Scalable Computational Method for Dynamic Integration of Multiple Molecular Pathway Models
Ayyadurai, V. A. S., & Dewey, C. F. (2010) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-010-0143-x · Cited by 43
A phase I dose escalation study of oral MK-2206 (allosteric Akt inhibitor) with oral selumetinib (AZD6244; ARRY-142866) (MEK 1/2 inhibitor) in patients with advanced or metastatic solid tumors.
Khan, K. H., Yan, L., Mezynski, J., Patnaik, A., Moreno, V., Papadopoulos, K. P., Garrett, C. R., Ong, M., Shannon, K. A., Morosky, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.e13599 · Cited by 36
Surface immunoglobulin positive lymphocytes in human breast cancer tissue and homolateral axillary lymph nodes
Richters, A., & Kaspersky, C. L. (1975) · Cancer · doi:10.1002/1097-0142(197501)35:1 · Cited by 35
A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors.
Tolcher, A. W., Baird, R. D., Patnaik, A., Garcia, V. M., Papadopoulos, K. P., Garrett, C. R., Olmos, D., Shannon, K., Zazulina, V., Rubin, E. H., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3004 · Cited by 35
Kinetic simulation of anticancer drug interactions
Jackson, R. (1980) · International Journal of Bio-Medical Computing · doi:10.1016/0020-7101(80)90045-8 · Cited by 28
ROCK: a breast cancer functional genomics resource
Sims, D., Bursteinas, B., Gao, Q., Jain, E., Mackay, A. G., Mitsopoulos, C., & Zvelebil, M. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0945-5 · Cited by 26
Analysis of Compound Synergy in High-Throughput Cellular Screens by Population-Based Lifetime Modeling
Peifer, M., Weiss, J. M., Sos, M. L., Koker, M., Heynck, S., Netzer, C., Fischer, S., Rode, H. B., Rauh, D., Rahnenführer, J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008919 · Cited by 24
Modeling of Protein Signaling Networks in Clinical ProteomicsPreprint
Geho, D. H., Petricoin, E. F., Liotta, L. A., & Araujo, R. P. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.022 · Cited by 20
Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).
Infante, J. R., Falchook, G. S., Lawrence, D. P., Weber, J. S., Kefford, R. F., Bendell, J. C., Kurzrock, R., Shapiro, G. I., Kudchadkar, R. R., Long, G. V., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.cra8503 · Cited by 20
Enzyme kinetics and combination chemotherapy: An appraisal of current concepts
Harrap, K. R., & Jackson, R. (1975) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(75)90009-6 · Cited by 18
Personalized Medicine: Patient-Predictive Panel Power
Workman, P., Clarke, P. A., & Al‐Lazikani, B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.030 · Cited by 16
Self-citation
The combination of cytotoxic and molecularly targeted therapies – can it be done?
Jackman, A. L., Kaye, S. B., & Workman, P. (2004) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2004.11.012 · Cited by 16
Self-citation
Will Hsp90 Inhibitors Prove Effective in BRAF-Mutant Melanomas?
Catalanotti, F., & Solit, D. B. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0626 · Cited by 14
A phase I study of bevacizumab in combination with sunitinib, sorafenib, and erlotinib plus cetuximab, and trastuzumab plus lapatinib.
Falchook, G. S., Wheler, J. J., Naing, A., Hong, D. S., Moulder, S. L., Piha-Paul, S. A., Ng, C. S., Jackson, E., & Kurzrock, R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.2512 · Cited by 12

Flagged first, then by citations

Research works printed but not linked: 1

Goldie, J.H. & Coldman, A.J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63, 1727–1733 (1979).

Sorted by citations

Skepinone-L, a Novel Potent and Highly Selective Inhibitor of p38 MAP Kinase, Effectively Impairs Platelet Activation and Thrombus Formation
Borst, O., Walker, B., Münzer, P., Russo, A., Schmid, E., Faggio, C., Bigalke, B., Laufer, S., Gawaz, M., & Lang, F. J. W. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350110 · Cited by 1,867
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279
Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset
Seashore-Ludlow, B., Rees, M. G., Cheah, J. H., Cokol, M., Price, E. V., Coletti, M. E., Jones, V., Bodycombe, N. E., Soule, C. K., Gould, J., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0235 · Cited by 813
“Combination treatments may mitigate the development of the drug resistance often observed with single-treatment therapies (42), yet principled methods to identify effective combinations have yet to be defined.”
Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges
Day, C.-P., Merlino, G., & Van Dyke, T. (2015) · Cell · doi:10.1016/j.cell.2015.08.068 · Cited by 676
DeepSynergy: predicting anti-cancer drug synergy with Deep Learning
Preuer, K., Lewis, R. P. I., Hochreiter, S., Bender, A., Bulusu, K. C., & Klambauer, G. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx806 · Cited by 668

See all 1,070

Authors: Al-Lazikani, B., Banerji, U., & Workman, P.
Affiliations: Royal Marsden NHS Foundation Trust (GB)
Institute of Cancer Research (GB)
Corresponding author: Banerji, Udai
Workman, Paul
ORCID: Banerji, Udai
Workman, Paul
Venue: Nature Biotechnology
Publisher: Springer Science and Business Media LLC
Published: 2012-07
Volume: 30
Issue: 7
Pages: 679-692
ISSN: 0733-222X (ISSN-L)
1087-0156
1546-1696
DOI: 10.1038/nbt.2284
OpenAlex: W2061061337
Cited by: 1,070
References: 172
Citations by year: 2026: 63 · 2025: 80 · 2024: 71 · 2023: 73 · 2022: 87 · 2021: 73 · 2020: 80 · 2019: 91 · 2018: 81 · 2017: 76 · 2016: 83 · 2015: 90 · 2014: 69 · 2013: 46 · 2012: 6
FWCI: 5.04
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Biotechnology (publishedVersion)
PubMed (publishedVersion)
Funders: NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
Cancer Research UK (C309/8992, 11566, C309/A8274)
National Institute for Health and Care Research
National Institutes of Health
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords: combination therapy, targeted cancer therapy, driver mutations, synthetic lethality, tumor vulnerability, precision oncology, acquired drug resistance, de novo resistance, polygenic resistance, cytotoxic chemotherapy
MeSH terms: Antineoplastic Combined Chemotherapy Protocols, Clinical Trials as Topic, Combined Modality Therapy, Humans, Neoplasms, Drug Design, Genome, Human, Genetic Heterogeneity, Metabolic Networks and Pathways, Precision Medicine, Molecular Targeted Therapy, High-Throughput Nucleotide Sequencing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Combinatorial drug therapy for cancer in the post-genomic era

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks